Company news

GSK plc news in 2024

GSK plc's news releases, calls and decks from 2024, newest first.

View company

New Phase III Jemperli data in endometrial cancer

March 18, 2024

GSK announces positive Blenrep DREAMM-8 results

March 7, 2024

ViiV LAI vs oral SOC data in adherence-challenged

March 6, 2024

GSK Annual Report 2023 on Form 20-F

March 5, 2024

New ViiV LA formulation potential 4-month dosing

March 5, 2024

GSK publishes Annual Report 2023

March 1, 2024

GSK announces positive EAGLE-1 headline results

February 26, 2024

ViiV LAI superior to orals in adherence-challenged

February 21, 2024

Julie Brown - External Appointment

February 20, 2024

GSK completes acquisition of Aiolos Bio

February 15, 2024

Director/PDMR Shareholding - Replacement

February 13, 2024

US FDA Fast Track designation for bepirovirsen

February 12, 2024

FDA accepts Arexvy filing for adults 50-59 at risk

February 6, 2024

Shingrix 18+ at risk China filing review accepted

February 6, 2024

GSK presents positive DREAMM-7 phase III data

February 6, 2024

EMA accepts Arexvy filing for adults 50-59 at risk

January 29, 2024

European Commission authorises Omjjara in the EU

January 29, 2024

Holding(s) in Company

January 18, 2024

Nucala approved in China for use in severe asthma

January 10, 2024

GSK enters agreement to acquire Aiolos Bio

January 9, 2024

← Newer news releases

Calls in 2024

Decks in 2024